{
    "name": "bempedoic acid/ezetimibe",
    "comment": "Rx",
    "other_names": [
        "Nexlizet"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "2-Azetidinones",
        "Lipid-Lowering Agents",
        "ACL Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/nexlizet-bempedoic-acid-ezetimibe-1000355",
    "pregnancy": {
        "common": [
            "Discontinue bempedoic acid/ezetimibe when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus ",
            "Decreases cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol; therefore, bempedoic acid/ezetimibe may cause fetal harm when administered to pregnant women based on the mechanism of action ",
            "No available data regarding use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Note: Statins are contraindicated in pregnant women"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Treatment of hyperlipidemia is not generally necessary during pregnancy",
                    "Cholesterol and cholesterol derivatives are needed for normal fetal development"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Bempedoic acid was not teratogenic in rats and rabbits when administered at doses resulting in exposures up to 11 and 12 times, respectively, the human exposures at the maximum clinical dose, based on AUC",
                    "In embryofetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of maternal toxicity or embryofetal teratogenic or toxicologic effects at exposures up to 10 and 150 times the human exposure, respectively, based on AUC"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding drug presence of bempedoic acid in human or animal milk, effects on breastfed infants, or effects on milk production; ezetimibe is present in rat milk, and therefore is likely present in human milk ",
            "Since bempedoic acid and ezetimibe decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, these actions may cause harm to the breastfed infant",
            "Based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity to ezetimibe, including anaphylaxis, angioedema, rash, and urticaria"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Hyperuricemia",
                    "description": [
                        "Bempedoic acid inhibits renal tubular OAT2 and may increase blood uric acid levels",
                        "Elevated uric acid levels usually occurred within the first 4 weeks of treatment initiation and persisted throughout treatment; elevated blood uric acid may lead to gout"
                    ]
                },
                {
                    "type": "Tendon rupture",
                    "description": [
                        "Bempedoic acid associated with increased risk of tendon rupture or injury",
                        "Tendon rupture occurred within weeks to months of initiating",
                        "May occur more frequently in patients aged â‰¥60 yr",
                        "Discontinue immediately if tendon rupture occurs",
                        "Consider discontinuing with joint pain, swelling, or inflammation"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Simvastatin or pravastatin",
                        "Bempedoic acid increases simvastatin or pravastatin serum concentrations which, may increase simvastatin/pravastatin-related myopathy",
                        "Avoid use with simvastatin doses >20 mg",
                        "Avoid use with pravastatin doses >40 mg",
                        "Atorvastatin and rosuvastatin: Elevations of 1.7-fold in AUC of atorvastatin, rosuvastatin, and/or their major metabolites were observed with bempedoic acid coadministration, suggesting a weak interaction; these elevations were generally within the individual statin exposures and do not affect dosing recommendations",
                        "Cyclosporine",
                        "Coadministration of cyclosporine and ezetimibe increases both cyclosporine and ezetimibe concentrations",
                        "If coadministered, monitor cyclosporine concentrations",
                        "Fibrates",
                        "Both fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis",
                        "Coadministration of ezetimibe with fibrates other than fenofibrate is not recommended",
                        " If cholelithiasis suspected, gallbladder studies are indicated",
                        "Consider alternant lipid-lowering therapies",
                        "Cholestyramine",
                        "Coadministration of cholestyramine and ezetimibe decreases ezetimibe concentration, which may lead to reduced efficacy",
                        "Administer ezetimibe-containing products at least 2 hr before or 4 hr after bile acid sequestrants"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine, ezetimibe.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Monitor for potential adverse effects of cyclosporine and ezetimibe if coadministered, especially in patients with severe renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of ezetimibe by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, an OATP1B1 and OATP1B3 inhibitor, may increase systemic exposure of these substrates "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of ezetimibe by  Other (see comment). Avoid or Use Alternate Drug. Trofinetide (an OATP131 and OATP13B inhibitor) may increase plasma levels of OATP131 or OATP13B substrates. Avoid coadministration with sensitive substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zavegepant intranasal",
            "description": {
                "common": "ezetimibe will increase the level or effect of zavegepant intranasal by  Other (see comment). Avoid or Use Alternate Drug. NTCP inhibitors may result in a significant increase in systemic exposure of zavegepant (a NTCP substrate)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of ezetimibe by  increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and weakly induces OATP1B1 and may decrease systemic exposure of drugs that are substrates of both UGT and OATP1B1."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of ezetimibe by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2-4 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of ezetimibe by  Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a OATP1B1 inhibitor) may increase the concentration and toxicities of OATP1B1 substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of ezetimibe by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir will increase the level or effect of ezetimibe by  Other (see comment). Use Caution/Monitor. Coadministration with glecaprevir/pibrentasvir may increase plasma concentration of drugs that are substrates of OATP1B1 or OATP1B3"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of ezetimibe by Other (see comment). Use Caution/Monitor. \nComment: Letermovir, an OATP1B1/3 inhibitor may increase plasma concentrations of coadministered OATP1B1/3 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pravastatin",
            "description": {
                "common": "bempedoic acid increases levels of pravastatin by unknown mechanism. Modify Therapy/Monitor Closely. Avoid concomitant use with pravastatin dose 40 mg."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "simvastatin",
            "description": {
                "common": "bempedoic acid increases levels of simvastatin by unknown mechanism. Modify Therapy/Monitor Closely. Avoid concomitant use with simvastatin dose >20 mg."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "sofosbuvir/velpatasvir increases levels of ezetimibe by Other (see comment). Use Caution/Monitor. \nComment: Velpatasvir inhibits OATP1B1, OATP1B3, and OATP2B1 transporters. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "fenofibrate increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "fenofibrate micronized increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "fenofibric acid increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil increases levels of ezetimibe by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin will increase the level or effect of ezetimibe by  Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infection",
            "percent": "4.5"
        },
        {
            "name": "Muscle spasms",
            "percent": "3.6"
        },
        {
            "name": "Hyperuricemia",
            "percent": "3.5"
        },
        {
            "name": "Back pain",
            "percent": "3.3"
        },
        {
            "name": "Abdominal pain or discomfort",
            "percent": "3.1"
        },
        {
            "name": "Bronchitis",
            "percent": "3"
        },
        {
            "name": "Pain in extremity",
            "percent": "3"
        },
        {
            "name": "Anemia",
            "percent": "2.8"
        },
        {
            "name": "Elevated liver enzymes",
            "percent": "2.1"
        },
        {
            "name": "Gout",
            "percent": "1.5"
        },
        {
            "name": "Benign prostatic hyperplasia",
            "percent": "1.3"
        },
        {
            "name": "Atrial fibrillation",
            "percent": "1.7"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "4.3"
        },
        {
            "name": "Diarrhea",
            "percent": "4.1"
        },
        {
            "name": "Arthralgia",
            "percent": "3"
        },
        {
            "name": "Sinusitis",
            "percent": "2.8"
        },
        {
            "name": "Pain in extremity",
            "percent": "2.7"
        },
        {
            "name": "Fatigue",
            "percent": "2.4"
        },
        {
            "name": "Influenza",
            "percent": "2"
        },
        {
            "name": "Tendon rupture",
            "percent": "0.5"
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including anaphylaxis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "and urticaria",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Elevated creatinine phosphokinase",
            "percent": null
        },
        {
            "name": "Myopathy",
            "percent": null
        },
        {
            "name": "rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Elevated liver transaminases",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Cholelithiasis",
            "percent": null
        },
        {
            "name": "Cholecystitis",
            "percent": null
        }
    ]
}